“Don’t just target the cancer cell—focus on the stroma too.” That’s the key message from Dr. Jonathan Pachter, Chief Scientific Officer at Verastem Oncology, in our exclusive interview about the company’s bold strategy to combat aggressive cancers like pancreatic and low-grade serous ovarian cancer (LGSOC).
Verastem is redefining cancer treatment by targeting both the tumour microenvironment and oncogenic drivers such as the RAS/MAPK pathway. Their innovative combinations—like avutometinib + defactinib—don’t just halt tumor growth; they break down the barriers that prevent immune cells and chemotherapy from reaching the tumor.
Early data is promising: In the RAMP 205 trial, this approach delivered an 83% partial response rate in metastatic pancreatic cancer patients. And with the FDA’s recent accelerated approval of the AVMAPKI™ FAKZYNJA™ combo for KRAS-mutant LGSOC, Verastem’s science is already reaching the clinic.
Through global partnerships, synergistic pipelines, and deep engagement with patient communities, Verastem is paving a new path in oncology—one that’s collaborative, targeted, and patient-first.
Read the full in-depth interview article here: https://bit.ly/3ZjUI6Y
